Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010554 | 1.00 | HSD11B1 (0.75) | HSD11B1RAB9AEPHX2MAPK1USP2 | |
| SCHEMBL4142798 | 0.91 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHRALDH1A1 | |
| SCHEMBL4009206 | 0.91 | HSD11B1 (0.68) | HSD11B1ALDH1A1 | |
| SCHEMBL4009203 | 0.91 | HSD11B1 (0.68) | HSD11B1ALDH1A1 | |
| SCHEMBL4006575 | 0.90 | HSD11B1 (0.88) | HSD11B1RAB9AEPHX2 | |
| SCHEMBL4006568 | 0.90 | HSD11B1 (0.88) | HSD11B1RAB9AEPHX2 | |
| SCHEMBL4011649 | 0.90 | HSD11B1 (0.71) | HSD11B1RAB9AEPHX2MAPK1LMNA | |
| SCHEMBL4011655 | 0.90 | HSD11B1 (0.71) | HSD11B1RAB9AEPHX2MAPK1LMNA | |
| SCHEMBL5950609 | 0.89 | HSD11B1 (0.90) | HSD11B1RAB9AEPHX2TSHR | |
| SCHEMBL4138538 | 0.89 | HSD11B1 (0.70) | HSD11B1RAB9AEPHX2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885RAB9A 1641/4885EPHX2 788/4885 |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | HSD11B1 1/4885RAB9A 2691/4885EPHX2 1175/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885RAB9A 2077/4885EPHX2 1552/4885 |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885RAB9A 1580/4885EPHX2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.